Trever G. Bivona, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Trever G. Bivona, MD, PhD

Associate Professor, Hematology and Oncology, UCSF

TBivona@medicine.ucsf.edu

Phone: (415) 885-3882 [Clinic]; (415) 353-9927 [Asst]; (415) 476-9907 [lab]
600 16th Street
San Francisco, CA 94158

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics» Cancer Genetics

Research Summary

I am a medical oncologist with a PhD in cell and molecular biology. I maintain an active academic clinical practice and lead a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. I have discovered several mechanisms of resistance to EGFR-targeted therapy, BRAF- and MEK-targeted therapy, and ALK-targeted therapy in lung and other cancers. I direct a multi-disciplinary team engaged in laboratory-based patient-focused research, and I am an investigator on clinical trials, including rational upfront polytherapy trials designed to forestall and eliminate resistance and that are motivated by my laboratory-based discoveries.

Education

Vanderbilt University, B.S., 1998, Molecular Biology
New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
New York University, School of Medicine, M.D., 2005, Medicine
Brigham and Women’s Hospital/Harvard, 2005-2007, Internal Medicine
Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology


Professional Experience

  • 1998-2005
    MD-PhD, Medical Scientist Training Program, NYU School of Medicine
  • 2005-2007
    Resident House Staff, Internal Medicine, Brigham and Women’s Hospital
  • 2007-2011
    Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center
  • 2008-2011
    Research Fellow, Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
  • 2011-2015
    Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco
  • 2011- present
    Member, UCSF Helen Diller Comprehensive Cancer Center
  • 2011- present
    Faculty Member, California Institute for Quantitative Biosciences (QB3)
  • 2015-present
    Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

Honors & Awards


  • 1998
    Vanderbilt University Honors Degree in Molecular Biology
  • 1998
    Vanderbilt University Research Excellence Award
  • 1998-2005
    NIH Medical Scientist Training Program Award
  • 2005
    Medical Science Writing Award, NYU School of Medicine
  • 2007
    US Patent 20060083742 Prenyl-electrostatic Switch
  • 2008-2010
    Charles A. Dana Foundation Clinical Scholars Research Fellowship
  • 2009
    Julia Zelmanovich Young Alumnus Award, NYU School of Medicine
  • 2010
    American Society of Clinical Oncology Young Investigator Award
  • 2010
    Uniting Against Lung Cancer Research Investigator
  • 2011
    NIH/NCI Clinical Investigator Career Development Award (K08)
  • 2012
    National Lung Cancer Partnership Young Investigator Award
  • 2012
    Sidney Kimmel Foundation Kimmel Scholar Award
  • 2012
    Damon Runyon Clinical Investigator Award Finalist
  • 2012
    Doris Duke Clinical Scientist Development Award
  • 2012
    American Lung Association Lung Cancer Discovery Award
  • 2012
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2012
    Visiting Scholar Howard Hughes Medical Institute (HHMI) Scholars Program at California, State University-Fullerton
  • 2012
    NIH Director's New Innovator Award (DP2)
  • 2013
    Searle Scholar Award
  • 2014
    Lung Cancer Innovators Award (Addario and Van Auken Foundations)
  • 2015
    Pew-Stewart Scholar, Pew Charitable Trust

Selected Publications

  1. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6.
    View on PubMed
  2. RAS-MAPK in ALK targeted therapy resistance. Cell Cycle. 2015 Dec 2; 14(23):3661-2.
    View on PubMed
  3. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
    View on PubMed
  4. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  5. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015 Jun 18; 14(12):1765-6.
    View on PubMed
  6. Oncogenic activation of the PI3-kinase p110ß isoform via the tumor-derived PIK3Cß(D1067V) kinase domain mutation. Oncogene. 2015 May 18.
    View on PubMed
  7. AXL Mediates Resistance to PI3Ka Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell. 2015 Apr 13; 27(4):533-46.
    View on PubMed
  8. NF-?B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Rep. 2015 Apr 7; 11(1):98-110.
    View on PubMed
  9. AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells. PLoS One. 2015; 10(3):e0119832.
    View on PubMed
  10. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene. 2015 Feb 23.
    View on PubMed
  11. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View on PubMed
  12. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014; 12(1):355.
    View on PubMed
  13. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004.
    View on PubMed
  14. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 Apr 1; 20(7):2001-10.
    View on PubMed
  15. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57.
    View on PubMed
  16. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28.
    View on PubMed
  17. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321.
    View on PubMed
  18. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013 Aug 24; 382(9893):720-31.
    View on PubMed
  19. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9.
    View on PubMed
  20. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013 Apr; 14(4):304-14.
    View on PubMed

Go to UCSF Profiles, powered by CTSI